2^nd International Conference & Exhibition on Tissue preservation and Bio-banking September 12-13, 2016 Philadelphia, USA

Stem cells contribute to innate healing and harbor a promising role for regenerative medicine. Stem cell banking through long-term storage of different stem cell platforms represents a fundamental source to preserve original features of stem cells for patient-specific clinical applications. Stem cell research and clinical translation constitute fundamental and indivisible modules catalyzed through biobanking activity, generating a return of investment.

The sequencing of the human genome, completed at the dawn of the twenty-first century, allows researchers to integrate new data on genetic risk factors with demographic and lifestyle data collected via modern communication technologies. The technical prerequisites now exist for merging these cascades of molecular genetic information, not only to national health registers, but also to epidemiology and clinical data. Long-term storage of biological materials and data is a critical component of any epidemiological or clinical study. In designing Biobanks, informatics plays a vital role for the handling of samples and data in a timely fashion. Biobank Informatics contains important elements concerning definition, structure, and standardization of information that has been gathered from a multitude of sources from population-based registries, biobanks, patient records, and from large-scale molecular measurements.

Bioinformatics for Big Data San Francisco, USA, Immuno-Oncology London UK, Next-Generation Cancer Immunotherapies San Diego, USA, ESBB conference Johannesburg, South Africa, Global Biobanking London, UK, Keystone Stem Cells and Regeneration in the Digestive Organs (X6) Keystone, Colorado, USA, ISSCR Pluripotency: From basic science to therapeutic applications Kyoto, Japan, Keystone Cardiac Development, Regeneration and Repair (Z2) Snowbird, Utah, USA, The Stem Cell Niche–Development & Disease Hillerød, Denmark, EMBL Hematopoietic Stem Cells: From the Embryo to the Aging Organism Heidelberg, Germany

Biorepositories provide a resource for researchers to increase understanding of complex diseases. Studies such as the Lung Genomics Research Consortium (LGRC), a two-year project launched in October 2009, are going a step further than standard biobanking practices and characterizing the samples with their molecular makeup. The molecular data can then be mined along with the clinical data. Led by National Jewish Health and funded by the National Heart, Lung and Blood Institute, a division of the National Institutes of Health (NIH), the LGRC project consists of five institutions, including Dana-Farber Cancer Institute. Collaborators in the project work with samples banked at the Lung Tissue Research Consortium (LTRC), which houses tissue samples and blood from lung disease sufferers, primarily chronic obstructive pulmonary disease (COPD), along with a rich set of clinical data from patients

Immuno-Oncology London UK, Next-Generation Cancer Immunotherapies San Diego, USA, ESBB conference Johannesburg, South Africa, HandsOn Biobanks 2016 conference Vienna, Austria, American Society for Bioethics and Humanities Houston, USA, Craniofacial Morphogenesis & Tissue Regeneration Ventura, CA, USA, ISSCR Pluripotency: From basic science to therapeutic applications Kyoto, Japan, Craniofacial Morphogenesis & Tissue Regeneration Ventura, CA, USA, Phacilitate Cell & Gene Therapy World Washington D.C., USA, Notch Signaling in Development, Regeneration & Disease Gordon Research Conference Lewiston, ME, USA.

The biobanking market is poised for explosive growth if it can overcome the challenges of an adolescent industry. According to an August 2012 Infiniti Research report titled “Global Biobanking Market 2011-2015,” the biobanking market will increase 30 per cent from 2011 to 2015 to nearly $183 billion.¹ Growth is being driven by an increase in population genetics studies, personalized medicine, and the use of genetic information in food safety, forensics, and disease surveillance.

The stated aim of the Genomics and Personalized Medicine Act is to secure the promise of personalized medicine for all Americans by expanding and accelerating genomics research and initiatives to improve the accuracy of disease diagnosis, increase the safety of drugs, and identify novel treatments, and for other purposes. This past May, Congressman Patrick Kennedy (D-RI) and Congresswoman Anna Eshoo (D-CA) re-introduced a personalized medicine bill to the U.S. House of Representatives. The bill was originally introduced in 2006 by then-Senator from Illinois Barack Obama. While HR 5440, also known as the Genomics and Personalized Medicine Act of 2010 (GPMA 2010) Despite its narrow definition of personalized medicine, GPMA 2010 includes several expansive initiatives. GPMA 2010 would appropriate $150 million for fiscal year 2011 to accomplish these initiatives, including the creation of an Office of Personalized Healthcare and several committees to address translational challenges of personalized medicine, the standardization of the collection of human biological samples, the funding of further research and education on personalized medicine, and the creation of a national Biobanks.

Genomic Sample Prep and Biomarker Assay Development San Francisco, USA, Managing Biomarker-Driven Clinical Trials Miami, USA, The Biomarker Conference Orlando, Florida, USA, ART World Congress Symposium on Safe and Efficient IVF New York City, USA, World Conference on Regenerative Medicine 2015 Leipzig, Germany, Craniofacial Morphogenesis & Tissue Regeneration Ventura, CA, USA, Keystone Stem Cells and Cancer Breckenbridge, CO, USA, Keystone Stem Cells and Regeneration in the Digestive Organs (X6) Keystone, Colorado, USA, Stem Cells: from Basic Biology to Therapeutic Application Suzhou, China, EMBL Hematopoietic Stem Cells: From the Embryo to the Aging Organism Heidelberg, Germany.

In 2008 United States researchers stored 270 million specimens in biobanks, and the rate of new sample collection was 20 million per year. These numbers are large and representative of a fundamental worldwide change in the nature of research between the time when such numbers of samples could not be used and the time when researchers began demanding them.Collectively, researchers began to progress beyond single-center research centers to a next-generation qualitatively different research infrastructure. Some of the challenges raised by the advent of biobanks are ethical, legal, and social issues pertaining to their existence, including the fairness of collecting donations from vulnerable populations, providing informed consent to donors, the logistics of data disclosure to participants, the right to ownership of intellectual property, and the privacy and security of donors who participate. Because of these new problems, researchers and policymakers began to require new systems of research governance.

Disease-oriented biobanks (which may also be referred to as clinical biobanks) are placed at the interface between clinical practice and research. They collect biological samples from patients, aiming at discovery and validation of genetic and non-genetic risk factors of diseases. They are usually established in hospitals and research institutes, and multi-centre collections can raise from clinical trials and genetic studies. Two domains of clinical biobanks can be distinguished: tissue banks and rare disease biobanks. They represent disease-oriented biobanks as they collect samples and data within the context of clinical care. Biological materials found in such biobanks are collected from patients and represent residual material of samples taken as part of an exploration or a clinical follow-up. Samples for clinical studies and diagnostic purposes have been collected throughout the history of medicine.

World Conference on Regenerative Medicine 2015 Leipzig, Germany, Biomarkers for Cancer Immunotherapy San Francisco, USA, Biomarkers & Diagnostics World Congress Philadelphia, USA, ESBB conference Johannesburg, South Africa, ART World Congress Symposium on Safe and Efficient IVF New York City, USA, Keystone Cardiac Development, Regeneration and Repair (Z2) Snowbird, Utah, USA, Phacilitate Cell & Gene Therapy World Washington D.C., USA, Keystone Stem Cells and Cancer Breckenbridge, CO, USA, Keystone Stem Cells and Regeneration in the Digestive Organs (X6) Keystone, Colorado, USA, World Conference on Regenerative Medicine 2015 Leipzig Germany.

Biobanking of the human samples to support translational research is a global movement and is now being well established across all continents. Major challenges lie in the fact on how to obtain; process and supply samples to support research projects. Biobanking activities overlap with the Anatomical Pathology activities. Collection, embedding, sectioning and storing of collected samples are done daily. All samples are provided to the researcher with the de-identified path report and verification. Researchers usually concentrate on gene expression techniques. When it comes to protein expression in the tissue, immunohistochemistry is method performed. Diagnostic laboratories perform routine immunohistochemistry on a large number of more commonly used antibodies such AE1/AE3; CD45;ER/PR/Her2. Diagnostic laboratories have no spare time that is required to standardize and optimize novel antibodies which researchers are applying in their study. This is the point where we are able to offer support and utilize resources with a dual benefit. We have been optimizing anti NR1D1 (nuclear receptor for squamous cell carcinoma) for thyroid study; caspase 3, 8 and 9 (cell apoptosis) in breast cancer study; F4/80 in mouse model for macrophage/inflammation detection just to mention few. We support research work and continue to learn more about possibilities of immunohistochemistry. All slides obtained are scanned to get digital image. All results obtained from immunohistochemistry are interpreted by anatomical pathologist.

Genomic Sample Prep and Biomarker Assay Development San Francisco, USA, Cancer Immunotherapy San Francisco, USA, Biomarkers for Cancer Immunotherapy San Francisco, USA, Biomarkers & Diagnostics World Congress Philadelphia, USA, Keystone Cardiac Development, Regeneration and Repair (Z2) Snowbird, Utah, USA, The Stem Cell Niche–Development & Disease Hillerød, Denmark, Molecular and Cellular Basis of Growth and Regeneration (A3) Breckenridge, Colorado, USA, Phacilitate Cell & Gene Therapy World Washington D.C., USA, Germline Stem Cells Conference, Abcam meeting before ISSCR San Francisco, California, USA, World Conference on Regenerative Medicine 2015 Leipzig, Germany.

According to estimates from the World Bank, global healthcare spending increased at a CAGR of 6.97% from 2003 to 2013, from USD 3,786 Billion in 2003 to USD 7,427 Billion in 2013. In this period, public healthcare spending increased at a CAGR of 7.28%, from USD 2,198 Billion in 2003 to USD 4,440 Billion in 2013. This high growth rate, along with the substantial size of healthcare spending, will act as an important driver for biobanks, hospitals and gene banks, which are the major end-user segments of the biopreservation media & equipment market.

A process where cells, whole tissues, or any other substances susceptible to damage caused by chemical reactivity or time are preserved by cooling to sub-zero temperatures. At low enough temperatures, any enzymatic or chemical activity which might cause damage to the material in question is effectively stopped. Cryopreservation methods seek to reach low temperatures without causing additional damage caused by the formation of ice during freezing. Traditional cryopreservation has relied on coating the material to be frozen with a class of molecules termed cryoprotectants. New methods are constantly being investigated due to the inherent toxicity of many cryoprotectants. By default it should be considered that Cryopreservation alters/compromises the structure and function of cells unless it is proven otherwise for a particular cell population. Tissue and fluid preservation, also known as biobanking, biorepository science, or cryopreservation often referred to as cryobanking has become mainstream and big business. According to research by the British Broadcasting Corporation, the global biobanking market in 2010 was over $140 billion dollars, with a projected 30% increase by the year 2015 towards fostering biobanking initiatives.

World Conference on Regenerative Medicine 2015 Leipzig, Germany, Biomarkers for Cancer Immunotherapy San Francisco, USA, Biomarkers & Diagnostics World Congress Philadelphia, USA, ESBB conference Johannesburg, South Africa, ART World Congress Symposium on Safe and Efficient IVF New York City, USA, Tissue Niches & Resident Stem Cells in Adult Epithelia Gordon Research Conference Hong Kong, China, EMBL Hematopoietic Stem Cells: From the Embryo to the Aging Organism Heidelberg, Germany, Keystone Cardiac Development, Regeneration and Repair (Z2) Snowbird, Utah, USA, Stem Cells: from Basic Biology to Therapeutic Application Suzhou, China, Keystone Stem Cells and Regeneration in the Digestive Organs (X6) Keystone, Colorado, USA.

Increase in funding for these studies and research of stem cells would also trigger the growth of this market. In 2013, the government of Japan funded around USD 1.12 billion for stem cell studies. Moreover, advancement in technologies may also boost the growth of this market. Medical experts are becoming increasingly inclined towards the use of bioengineered products, which are more compatible with the human body. Increase in drug manufacturing through stem cells will also enhance the growth of this market. Recently, stem cells proved to be helpful in treating spinal muscular atrophy. It has been reported that in 2013, around 30,000 kids in the U.S. suffer from spinal muscular atrophy. Stem cell-based drugs would help in curing such complex diseases, which would again support the growth of this market.

Although most living organisms are composed of large amounts of water, it is not inevitable that freezing these organisms results in ice-formation. Among amphibians and insects that can tolerate freezing, there is wide variation in the amount of freezing they can tolerate. Species of frogs can spend days or weeks "with as much as 65 percent of their total body water as ice". Some amphibians achieve their protection due to the glycerol manufactured by their livers. Glycerol is "antifreeze", it reduces ice formation and lowers freezing point. Glycerol (glycerin), like ethylene glycol (automobile anti-freeze) is cryoprotectants. The sugar glucose is also cryoprotectants — and arctic frogs have a special form of insulin that accelerates glucose release and absorption into cells as temperatures approach freezing. Cryoprotectants can make water harden like glass — with no crystal formation — a process called Vitrification. Freezing-damage to cells is due to the formation of ice-crystals. Entire organs can be solidified and stored at temperatures as low as -140° C. Scientists are working on ways to reduce the toxicity of the cryoprotectants used to make water vitrify to allow banking of organs for transplantation. At Alcor, we are optimistic that the toxicity that still does occur with vitrification of human organs will be reversible with future molecular repair technology.

World Conference on Regenerative Medicine 2015 Leipzig, Germany, HandsOn Biobanks 2016 conference Vienna, Austria, ESBB conference Johannesburg, South Africa, Global Biobanking London, UK, Genomic Sample Prep and Biomarker Assay Development San Francisco, USA, Keystone Stem Cells and Cancer Breckenbridge, CO, USA, ISSCR Pluripotency: From basic science to therapeutic applications Kyoto, Japan, Tissue Niches & Resident Stem Cells in Adult Epithelia Gordon Research Conference Hong Kong, China, Craniofacial Morphogenesis & Tissue Regeneration Ventura, CA, USA, Phacilitate Cell & Gene Therapy World Washington D.C., USA.

Increase in funding for these studies and research of stem cells would also trigger the growth of this market. In 2013, the government of Japan funded around USD 1.12 billion for stem cell studies. Moreover, advancement in technologies may also boost the growth of this market. Medical experts are becoming increasingly inclined towards the use of bioengineered products, which are more compatible with the human body. Increase in drug manufacturing through stem cells will also enhance the growth of this market. Recently, stem cells proved to be helpful in treating spinal muscular atrophy. It has been reported that in 2013, around 30,000 kids in the U.S. suffer from spinal muscular atrophy. Stem cell-based drugs would help in curing such complex diseases, which would again support the growth of this market.

The Germplasm Bank is committed to providing healthy and viable seed, as well as reliable information on the collections of maize and wheat genetic resources it preserves; carrying out the activities required for seed introduction, processing, conservation, and distribution; complying with international agreements and standards; and hiring qualified staff to ensure that the requirements of our clients are met. The Bank is thus committed to complying with ISO 9001:2008 and continually improving the effectiveness of the Quality Management System. The Global Plan of Action (GPA) for plant genetic resources for food and agriculture aims to promote the conservation, sustainable utilization, and fair and equitable sharing of benefits of plant genetic resources. It is designed to contribute to the implementation of the Convention on Biological Diversity in the field of food and agriculture. The Plant Genetic Resource Center's specially designed vaults currently hold some 28,000 samples of maize and teosinte, a wild relative of maize, and 140,000 Triticeae samples, including bread wheat, durum wheat, and triticale (a man-made crop developed by crossing wheat with rye), with significant collections of barley, rye, and primitive and wild relatives of wheat. The Center also maintains a living collection of Tripsacum, a more distant maize relative.

ESBB conference Johannesburg, South Africa, Global Biobanking London, UK, HandsOn Biobanks 2016 conference Vienna, Austria, Managing Biomarker-Driven Clinical Trials Miami, USA, Genomic Sample Prep and Biomarker Assay Development San Francisco, USA, 2nd International Symposium on Germplasm of Ornamentals Atlanta, Georgia, IX International Symposium on In Vitro Culture and Horticultural Breeding Giza, Egypt, International Symposium on Role of Plant Genetic Resources on Reclaiming Lands and Environment Deteriorated by Human and Natural Actions Shiraz, Iran, VIII International Postharvest Symposium: Enhancing Supply Chain and Consumer Benefits - Ethical and Technological Issues Cartagena, Murcia, Spain.

According to estimates from the World Bank, global healthcare spending increased at a CAGR of 6.97% from 2003 to 2013, from USD 3,786 Billion in 2003 to USD 7,427 Billion in 2013. In this period, public healthcare spending increased at a CAGR of 7.28%, from USD 2,198 Billion in 2003 to USD 4,440 Billion in 2013. This high growth rate, along with the substantial size of healthcare spending, will act as an important driver for biobanks, hospitals and gene banks, which are the major end-user segments of the biopreservation media & equipment market.

Fertility preservation is the effort to help cancer patients retain their fertility, or ability to procreate. Research into how cancer affects reproductive health and preservation options are growing, sparked in part by the increase in the survival rate of cancer patients. The main methods of fertility preservation are ovarian protection by GnRH agonists, cryopreservation of ovarian tissue, eggs or sperm, or of embryos after in vitro fertilization. The patient may also choose to use egg or sperm from a donor by third party reproduction rather than having biological children.

ART World Congress Symposium on Safe and Efficient IVF New York City, USA, Global Biobanking London, UK, The Biomarker Conference Orlando, Florida, USA, World Conference on Regenerative Medicine 2015 Leipzig, Germany, ESBB conference Johannesburg, South Africa, World Conference on Regenerative Medicine 2015 Leipzig Germany, Keystone Stem Cells and Regeneration in the Digestive Organs (X6) Keystone, Colorado, USA, Molecular and Cellular Basis of Growth and Regeneration (A3) Breckenridge, Colorado, USA, Keystone Cardiac Development, Regeneration and Repair (Z2) Snowbird, Utah, USA, Tissue Niches & Resident Stem Cells in Adult Epithelia Gordon Research Conference Hong Kong, China.

According to estimates from the World Bank, global healthcare spending increased at a CAGR of 6.97% from 2003 to 2013, from USD 3,786 Billion in 2003 to USD 7,427 Billion in 2013. In this period, public healthcare spending increased at a CAGR of 7.28%, from USD 2,198 Billion in 2003 to USD 4,440 Billion in 2013. This high growth rate, along with the substantial size of healthcare spending, will act as an important driver for biobanks, hospitals and gene banks, which are the major end-user segments of the biopreservation media & equipment market.

Millions of biological samples, including cells of human, animal or bacterial origin, viruses, serum/plasma or DNA/RNA, are stored every year throughout the world for diagnostics and research. The purpose of this review is to summarize the resources necessary to set up a bio-banking facility, the challenges and pitfalls of sample collection, and the most important techniques for separation and storage of samples. Biological samples can be stored for up to 30 years, but specific protocols are required to reduce the damage induced by preservation techniques. Software dedicated to biological banks facilitate sample registration and identification, the cataloguing of sample properties (type of sample/specimen, associated diseases and/or therapeutic protocols, environmental information, etc.), sample tracking, quality assurance and specimen availability. Bio-bank facilities must adopt good laboratory practices and a stringent quality control system and, when required, comply with ethical issues.

Biomarkers & Diagnostics World Congress Philadelphia, USA, Bioinformatics for Big Data San Francisco, USA, Immuno-Oncology London UK, Next-Generation Cancer Immunotherapies San Diego, USA, ESBB conference Johannesburg, South Africa, Stem Cells: from Basic Biology to Therapeutic Application Suzhou, China, Molecular and Cellular Basis of Growth and Regeneration (A3) Breckenridge, Colorado, USA, The Stem Cell Niche–Development & Disease Hillerød, Denmark, Germline Stem Cells Conference, Abcam meeting before ISSCR San Francisco, California, USA, World Conference on Regenerative Medicine 2015 Leipzig Germany.

According to estimates from the World Bank, global healthcare spending increased at a CAGR of 6.97% from 2003 to 2013, from USD 3,786 Billion in 2003 to USD 7,427 Billion in 2013. In this period, public healthcare spending increased at a CAGR of 7.28%, from USD 2,198 Billion in 2003 to USD 4,440 Billion in 2013. This high growth rate, along with the substantial size of healthcare spending, will act as an important driver for biobanks, hospitals and gene banks, which are the major end-user segments of the biopreservation media & equipment market.

Population banks: Biomarkers of susceptibility and population identity and their operational substrate is germinal-line DNA from a huge number of healthy donors, representative of a concrete country/region or ethnic cohort. Disease-oriented banks for epidemiology: biomarkers of exposure, using a huge number of samples, usually following a healthy exposed cohort/case–control design. Disease-oriented general biobanks (i.e. tumor banks): biomarkers of disease through prospective and/or retrospective collections of diseased tissues and non-diseased tissues and their derivate (DNA/RNA/proteins), usually associated to clinical data and some-times associated to clinical trials for prognostic, diagnostic and therapeutic purpose.

Managing Biomarker-Driven Clinical Trials Miami, Florida, USA, Genomic Sample Prep and Biomarker Assay Development San Francisco, USA, Cancer Immunotherapy San Francisco, USA, Biomarkers for Cancer Immunotherapy San Francisco, USA, Biomarkers & Diagnostics World Congress Philadelphia, USA, Molecular and Cellular Basis of Growth and Regeneration (A3) Breckenridge, Colorado, USA, Phacilitate Cell & Gene Therapy World Washington D.C., USA, Craniofacial Morphogenesis & Tissue Regeneration Ventura, CA, USA, Keystone Stem Cells and Cancer Breckenbridge, CO, USA, Keystone Stem Cells and Regeneration in the Digestive Organs (X6) Keystone, Colorado, USA.

According to estimates from the World Bank, global healthcare spending increased at a CAGR of 6.97% from 2003 to 2013, from USD 3,786 Billion in 2003 to USD 7,427 Billion in 2013. In this period, public healthcare spending increased at a CAGR of 7.28%, from USD 2,198 Billion in 2003 to USD 4,440 Billion in 2013. This high growth rate, along with the substantial size of healthcare spending, will act as an important driver for biobanks, hospitals and gene banks, which are the major end-user segments of the biopreservation media & equipment market.

Research utilizing human post-mortem brain tissue has played a critical role in propelling our knowledge of diseases and disorders of the nervous system .however declining autopsy rates combined with an increased demand for well-characterized, high-quality tissue requires a new approach to brain banking and better outreach and communication with stakeholders. The NBB will coordinate the collection, evaluation, processing, storage and distribution of nervous system tissue and associated clinical data via a federated network of brain and tissue repositories that span the United States in a transparent and standardized way for use by the broader research community for the study of neurological, psychiatric and developmental disorder. The U.S. National Institutes of Health is establishing a network of five brain Biobanks to unify and coordinate access to human brain tissue for neuroscience research. Goal of bio bank is to increase the availability of human disease and control brains and related bio specimens by increasing public awareness of the value of tissue donation for understanding brain disorders and facilitate the distribution of high-quality, well-characterized human-post mortem brain tissue for the research community.

Global Biobanking London, UK, The Biomarker Conference Orlando, Florida, USA, ESBB conference Johannesburg, South Africa, World Conference on Regenerative Medicine 2015 Leipzig, Germany, HandsOn Biobanks 2016 conference Vienna, Austria, Keystone Stem Cells and Cancer Breckenbridge, CO, USA, Keystone Stem Cells and Regeneration in the Digestive Organs (X6) Keystone, Colorado, USA, ISSCR Pluripotency: From basic science to therapeutic applications Kyoto, Japan, EMBL Hematopoietic Stem Cells: From the Embryo to the Aging Organism Heidelberg, Germany, Tissue Niches & Resident Stem Cells in Adult Epithelia Gordon Research Conference Hong Kong, China.

According to estimates from the World Bank, global healthcare spending increased at a CAGR of 6.97% from 2003 to 2013, from USD 3,786 Billion in 2003 to USD 7,427 Billion in 2013. In this period, public healthcare spending increased at a CAGR of 7.28%, from USD 2,198 Billion in 2003 to USD 4,440 Billion in 2013. This high growth rate, along with the substantial size of healthcare spending, will act as an important driver for biobanks, hospitals and gene banks, which are the major end-user segments of the biopreservation media & equipment market.

Ethical issues are commonly present in many aspects of Biobanking. The fact that Biobanks deal with human samples, invading an individual autonomy or limiting self-control, provokes a number of ethical issues. Who is actually competent to give informed consent and donate a sample? When individuals donate part of their body to a biobank, how is that human sample processed? Who is the owner of the sample? Who should decide how it should be used? Who has the right to know individual results of research? These and many more ethical dilemmas exist in the ethical framework of biobanks. With the recent rapid developments in biobanking, all of these issues are magnified with plenty of further new questions continuously arising. Ethical framework has been the most controversial issue in the domain of biobanking. Thus, it is not surprising that there is a substantial literature focusing on ethical dilemmas in biobanking, such as informed consent, privacy, protection, and returning of results to participants. For many years, researchers at CRB have provided constructive advice on how to deal with ethical aspects of research using human tissue material and personal data. For more than 80 years tissue has been derived from human bodies, stored, distributed and used for therapeutic, educational, forensic and research purposes as part of healthcare routine in most western countries.

American Society for Bioethics and Humanities Houston, USA, Association of Bioethics World Congress Edinburgh, UK, Oxford Global Health and Bioethics International Conference Oxfordshire, UK, CFP: Global Forum on Bioethics in Research Fondation Merieux, France, HandsOn Biobanks 2016 conference Vienna, Austria, Global Biobanking London, UK, The Biomarker Conference Orlando, Florida – USA, ART World Congress Symposium on Safe and Efficient IVF New York City, United States, VIII International Postharvest Symposium: Enhancing Supply Chain and Consumer Benefits - Ethical and Technological Issues Cartagena, Murcia, Spain.

According to estimates from the World Bank, global healthcare spending increased at a CAGR of 6.97% from 2003 to 2013, from USD 3,786 Billion in 2003 to USD 7,427 Billion in 2013. In this period, public healthcare spending increased at a CAGR of 7.28%, from USD 2,198 Billion in 2003 to USD 4,440 Billion in 2013. This high growth rate, along with the substantial size of healthcare spending, will act as an important driver for biobanks, hospitals and gene banks, which are the major end-user segments of the biopreservation media & equipment market.

The global biopreservation market is expected to reach USD 3,731.03 Million by 2020 from USD 2,150.48 Million in 2015, growing at a CAGR of 11.65% between 2015 and 2020. Biopreservation is used to ensure the stability, quality and purity of biospecimens. With a CAGR of 23.7%, global market value for cryopreservation equipment used in stem cells industry is anticipated to worth US$2.2 billion by 2015. On a global scale, North America accounts for nearly 35% of the market and will likely witness a higher growth rate in the upcoming years, in comparison with Asia-Pacific. While US accounts for the highest share of the global market value on a country basis, India and China surpasses the US in terms of growth rate anticipated in the near future. As per our analysis, freezers represent more than half of the cryopreservation equipment market value while cropreservative reagents stand for a share of close to 20%. The global biopreservation market is poised for rapid growth between 2015 and 2020. The drivers include increasing healthcare expenditure, growing demand for preserving new-born’s stem cells, increasing R&D spending on research, and increasing adoption of regenerative medicine.